[Neo-adjuvant chemotherapy for breast cancer]. 2001

J Shi, and G Fang, and Y Sheng
Changhai Hospital, Shanghai 200433, China.

OBJECTIVE To study the value and indications of a neo-adjuvant chemotherapy for breast cancers. METHODS Forty-three breast cancer patients were given the NF neo-adjuvant chemotherapy (Navelbine 25 mg/m2 and 5-Fu 500 mg/m2) for 3 cycles before the operation. Epirubicin (EPI 40 mg/m2) was added in patients with locally advanced lesions. G-CSF 75 micrograms subcutaneous injection was used to increase the white count as needed. RESULTS The overall response rate was 95.0%. Pre-operative neo-adjuvant chemotherapy showed CR in 3 patients (7.5%) and PR in 35 patients (87.5%) even though 2 patients (5.0%) were refractory. The follow-up ranged from 4 to 37 months (median 20 months). All patients are alive though 4 have developed recurrence or metastasis. CONCLUSIONS The pre-operative neo-adjuvant chemotherapy may preferably be given in 3 cycles from which those who benefit most are the breast cancer patients with inoperable lesions and who are planned to undergo breast-preserving surgery.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077235 Vinorelbine A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. 5'-Nor-anhydrovinblastine,KW 2307,KW-2307,Navelbine,Vinorelbine Tartrate,5' Nor anhydrovinblastine,KW2307
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic

Related Publications

J Shi, and G Fang, and Y Sheng
January 1993, European journal of cancer (Oxford, England : 1990),
J Shi, and G Fang, and Y Sheng
March 2020, Indian journal of surgical oncology,
J Shi, and G Fang, and Y Sheng
February 1999, Breast cancer research and treatment,
J Shi, and G Fang, and Y Sheng
February 2016, European journal of oncology nursing : the official journal of European Oncology Nursing Society,
J Shi, and G Fang, and Y Sheng
January 2016, The breast journal,
J Shi, and G Fang, and Y Sheng
September 2009, Breast cancer research and treatment,
J Shi, and G Fang, and Y Sheng
December 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique,
J Shi, and G Fang, and Y Sheng
July 2002, European radiology,
J Shi, and G Fang, and Y Sheng
January 2015, Indian journal of cancer,
J Shi, and G Fang, and Y Sheng
January 2018, South Asian journal of cancer,
Copied contents to your clipboard!